Coping and Perception of Prognosis in Patients With Indolent Non-Hodgkin’s Lymphoma

Author:

Newcomb Richard A12ORCID,Johnson P Connor12,Yang Daniel3,Holmbeck Katherine1,Choe Joanna1,Nabily Anisa1,Lark Porsha1,Dhawale Tejaswini12,Amonoo Hermioni L24,El-Jawahri Areej12ORCID

Affiliation:

1. Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital , Boston, MA , USA

2. Harvard Medical School , Boston, MA , USA

3. Duke University School of Medicine , Durham, NC , USA

4. Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute , Boston, MA , USA

Abstract

Abstract Background Indolent non-Hodgkin’s lymphomas (iNHL) are a heterogenous group of mostly incurable diseases with prolonged illness courses and prognostic uncertainty. Yet, studies evaluating coping and perception of prognosis are limited. Methods We conducted a cross-sectional study of adults newly diagnosed with iNHL in the past 3 months at a single academic center. We assessed quality of life (QOL: Functional Assessment of Cancer Therapy—General), psychological symptoms (Hospital Anxiety and Depression Scale), coping (Brief-COPE), and perception of prognosis (Prognosis Awareness Impact Scale). Results We enrolled 70.6% (48/68) of eligible patients. Patients had older age (mean = 66.9,sd = 10.5), were female (60.4%), predominantly identified as White (85.4%), and had at least received a college degree (75%). Chronic lymphocytic leukemia (39.6%) and follicular lymphoma (33.3%) were the most common diagnoses. Overall, 27.1% and 14.6% of patients reported clinically significant anxiety and PTSD symptoms, respectively. Patients highly utilized acceptance (56.2%), seeking emotional support (47.9%), and denial (47.9%) as coping strategies at diagnosis. While 66.7% of patients recalled their oncologist assessment of illness as incurable, only 35.4% reported that the illness is unlikely to be cured. Overall, 45.8% indicated that they were worried about prognosis and 31.2% reported perseverating on their prognosis. Higher emotional coping with prognosis was associated with fewer anxiety (B = −0.6, SE = 0.2, P < .001), depression (B = −0.3, SE = .1, P = .005), and PTSD (B = −1.3, SE = 0.4, P < .001) symptoms and better QOL (B = 1.7, SE = 0.4, P < .001). Discussion Patients with iNHL report substantial psychological distress, a diversity of coping strategies, and complex cognitive understanding of their prognosis. Interventions, which address prognostic uncertainty and promote positive emotional coping with prognosis, may ameliorate psychological distress in this population.

Funder

National Cancer Institute

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference46 articles.

1. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study);Rummel,2021

2. Low-grade lymphomas: new entities and treatment concepts;Hagemeister,1995

3. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a ­randomised, controlled, open-label, multicentre, phase 3 trial;Sehn,2016

4. Follicular Lymphoma;Welaya,2019

5. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures;Hallek,2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3